Abstract:Combination therapy via stimulus-responsive drug release is known to improve treatment efficacy and minimize side effects. However, the use of low-abundance cancer biomarkers as molecular triggers to induce efficient drug release for combination therapy still remains a challenge. Herein, we developed a dual microRNA-responsive drug nanocarrier for catalytic release of doxorubicin (Dox) and small interfering RNA (siRNA) in cancerous cells for combined chemotherapy and gene therapy with logic operation. The nanocarrier is constructed by assembling two duplexes of DNA/RNA and Dox molecules onto DNA-functionalized gold nanoparticles. Two microRNA molecules (miRNA-21 and miRNA-10b overexpressed in MDA-MB-231) could alternatively catalyze the disassembly of the nanocarrier through a thermodynamically driven entropy gain process, during which Dox molecules are released, and the two pairs of released DNA/RNA duplex hybridize to generate siRNA (siBcl-2) in situ by strand displacement reactions. Quantum dots are used to track the process in living cells. The AND logic gate-based drug release system allows effective treatment of specific cancer cell types according to miRNA expression patterns. This strategy represents an effective means to overcome multidrug resistance and improve therapeutic effects.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c09494?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c09494</a>.Materials and methods including characterization of GNPs (Figure S1), characterization of DNA2-QD (Figure S2), characterization of DNA hybridization (Figure S3), PAGE analysis of the strand displacement reaction (Figure S4), FL and ICP data for determination of the D1D′1C and D2DQ number (Figure S5), characterization of catalytic disassembly of Dox-GNC (Figure S6), stability test of Dox-GNC (Figure S7), agarose gel electrophoresis characterization of disassembly of GNC (Figure S8), determination of Dox loading on GNC (Figure S9), specificity of Dox-GNC triggered by dual miRNAs for drug release (Figure S10), stability of GNC at physiological circumstances (Figure S11), cell viabilities of three cell lines treated with GRR-Dox in the presence or absence of fuel DNA for different times (Figure S12), cell viabilities of MDA-MB-231 cells transfected with waste DNA (Figure S13), cell viabilities of MDA-MB-231 cells under different treatments (Figure S14), and expression level of the Bcl-2 protein measured with western blot (Figure S15) (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c09494/suppl_file/am0c09494_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Bioreduction-ruptured Nanogel for Switch On/off Release of Bcl2 Sirna in Breast Tumor Therapy.

A Networked Swellable Dextrin Nanogels Loading Bcl2 Sirna for Melanoma Tumor Therapy

Bioreducible, Arginine-Rich Polydisulfide-Based Sirna Nanocomplexes with Excellent Tumor Penetration for Efficient Gene Silencing.

Bioreducible Cross-Linked Hyaluronic Acid/Calcium Phosphate Hybrid Nanoparticles for Specific Delivery of siRNA in Melanoma Tumor Therapy.

Synthesis Of Ph-Sensitive Nanogels And Their Application In Sirna Delivery

Redox-responsive Mesoporous Silica Nanoparticles: a Physiologically Sensitive Codelivery Vehicle for Sirna and Doxorubicin.

Co-Delivery of Doxorubicin and Sirna with Reduction and Ph Dually Sensitive Nanocarrier for Synergistic Cancer Therapy

A Crosslinked Nucleic Acid Nanogel for Effective Sirna Delivery and Antitumor Therapy

Low-density Lipoprotein-Coupled Micelles with Reduction and Ph Dual Sensitivity for Intelligent Co-Delivery of Paclitaxel and Sirna to Breast Tumor

Injectable Supramolecular Hydrogels As Delivery Agents of Bcl‐2 Conversion Gene for the Effective Shrinkage of Therapeutic Resistance Tumors

Biocompatible Hydrogel Nanoparticles with Lysosomal Escape Properties for the Delivery of siRNA for the Gene Therapy of Colorectal Carcinoma

Stimuli-Responsive Polysaccharide Enveloped Liposome for Targeting and Penetrating Delivery of survivin-shRNA into Breast Tumor

“Stealth and Fully-Laden” Drug Carriers: Self-Assembled Nanogels Encapsulated with Epigallocatechin Gallate and Sirna for Drug-Resistant Breast Cancer Therapy

A Strategy Using Mesoporous Polymer Nanospheres As Nanocarriers of Bcl-2 Sirna Towards Breast Cancer Therapy

The Ph-Triggered Triblock Nanocarrier Enabled Highly Efficient Sirna Delivery for Cancer Therapy

Biodegradable Zwitterionic Nanogels with Long Circulation for Antitumor Drug Delivery.

Non-Cationic RGD-Containing Protein Nanocarrier for Tumor-Targeted siRNA Delivery

Dual MicroRNA-Triggered Drug Release System for Combined Chemotherapy and Gene Therapy with Logic Operation

Stimuli-Responsive and Highly Penetrable Nanoparticles As a Multifunctional Nanoplatform for Boosting Nonsmall Cell Lung Cancer Sirna Therapy

Folate-decorated PEGylated Triblock Copolymer As a Ph/reduction Dual-Responsive Nanovehicle for Targeted Intracellular Co-Delivery of Doxorubicin and Bcl-2 Sirna.

Enhanced Endosomal Escape of Dendrigraft Poly-L-lysine Polymers for the Efficient Gene Therapy of Breast Cancer